Transforming growth factor-beta (TGF-b) has a dual role in epithelial malignancies, including head and neck squamous cell carcinoma (HNSCC). Attenuation of canonical TGF-b signaling enhances de novo tumor development, whereas TGF-b overexpression and signaling paradoxically promotes malignant progression. We recently observed that TGF-b-induced growth arrest response is attenuated, in association with aberrant activation of nuclear factor-kB (NF-kB), a transcription factor, which promotes malignant progression in HNSCC. However, what role cross-talk between components of the TGF-b and NF-kB pathways plays in altered activation of these pathways has not been established. Here, we show TGF-b receptor II and TGF-b-activated kinase 1 (TAK1) are predominantly expressed in a subset of HNSCC tumors with nuclear activation of NF-kB family member RELA (p65). Further, TGF-b1 treatment induced sequential phosphorylation of TAK1, IKK, IkBa and RELA in human HNSCC lines. TAK1 enhances TGF-b-induced NF-kB activation, as TAK1 siRNA knockdown decreased TGF-b1-induced phosphorylation of IKK, IkB and RELA, degradation of IkBa, RELA nuclear translocation and DNA binding, and NF-kB-induced reporter and target gene transcription. Functionally, TAK1 siRNA inhibited cell proliferation, migration and invasion. Celastrol, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-b1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-b1-and tumor necrosis factor-alpha (TNF-a)-induced NF-kB reporter gene activity. Celastrol also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and Annexin V markers of apoptosis. Furthermore, TGF-b and RELA activation promoted SMAD7 expression. In turn, SMAD7 preferentially suppressed TGF-b-induced SMAD and NF-kB reporters when compared with constitutive or TNF-a-induced NF-kB reporter gene activation. Thus, cross-talk by TGF-b via TAK1 and NF-kB promotes the malignant phenotype of HNSCC. Moreover, NF-kB may contribute to the downstream attenuation of canonical TGF-b signaling through increased SMAD7 expression. Celastrol highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic TGF-b-NF-kB signal pathway.
INTRODUCTION
The role of transforming growth factor-beta (TGF-b) signaling in development of epithelial cancer is complex. In normal epithelial cells, TGF-b acts as a potent tumor suppressor through regulation of a variety of physiological processes, including growth inhibition and stimulation of apoptosis. 1 Subsequent inactivation of TGF-b signaling or key target genes can promote the de novo development of epithelial cancer. However, overexpression of TGF-b in such established cancer cells or the tumor microenvironment is often observed, and appears to have an important role in progression to a more invasive and metastatic phenotype. 2 Canonical TGF-b signaling is induced by ligand binding to receptor subunit TbRII, which in turn activates TbRI. TbRI phosphorylates SMAD2 and SMAD3, which associate as a heterodimeric complex with the common signaling mediator SMAD4, and together translocate into the nucleus to regulate gene expression. An inhibitor, SMAD7, may compete for binding with SMAD2 and 3 to the activated TGF-b receptor, thereby suppressing downstream TGF-b signaling. 3 Malignant cells can circumvent the suppressive effects of TGF-b through inactivation of key nodes along this pathway. 4 In human head and neck squamous cell carcinomas (HNSCC) arising from the upper aerodigestive tract, attenuated expression or genetic alteration of TbRII or SMAD4 is common. 5 Further, knockout of the genes encoding canonical pathway components promotes development of HNSCC in mice. [6] [7] [8] The mechanism(s) contributing to pathogenesis of the remaining cancers with intact TGFbRII/I-SMAD activation remains less clear. We recently observed that the TGF-b-induced growth arrest response is attenuated in the subset of HNSCC cell lines retaining TGF-b receptor II expression. 9 These HNSCC exhibited aberrant activation of signal-activated transcription factor nuclear factor-kB (NF-kB) target genes. Similar to the pro-oncogenic role of TGF-b, activation of NF-kB/RELA (p65) is implicated in cell proliferation, survival, malignant progression and poor prognosis of HNSCC, as well as other cancers. 10 We and others previously showed that NFkB/RELA may be partially inhibited by blockade of autocrine IL-1a and tumor necrosis factor-alpha (TNF-a), 11, 12 suggesting that other factors, may also contribute to NF-kB activation.
Interestingly, a TGF-b-activated kinase 1, TAK1, was previously shown to mediate responses to cytokines TNF-a or IL-1, and directly phosphorylate the inhibitor-kappaB kinase (IKK) complex that promotes activation of NF-kB. [12] [13] [14] TAK1 activation by TGF-b and these cytokines involves complex formation with associated linkers. [14] [15] [16] In turn, the IKK complex, formed by IKKa and IKKb catalytic subunits and a scaffold subunit, IKKg/NEMO, phosphorylates inhibitor-kBa (IkBa), which is ubiquitinylated and degraded by the proteasome. 17 IKK-mediated degradation of IkB promotes nuclear translocation and DNA binding of NF-kB, whereas IKK phosphorylation of the RELA (p65) subunit is required for transactivation of target genes. 18, 19 Of further potential interest, NF-kB as well as SMADs 2/3 can upregulate SMAD7, a negative feedback inhibitor of TGF-b-mediated activation of both canonical TGF-b-SMAD and TGF-b-TAK1 activation. [20] [21] [22] However, what role cross-talk and negative feedback between these components of the TGF-b and NF-kB pathways plays in altered activation of these pathways in HNSCC and other cancers is not well established.
Here, we examined the hypothesis that TGF-b activation via TAK1 contributes to aberrant NF-kB activation in HNSCC. We further explored the effects of TAK1 siRNA and a known TAK1 inhibitor, Celastrol, 23 to inhibit TAK1-mediated NF-kB signaling and the malignant phenotype in HNSCC. As NF-kB can induce SMAD7, we examined the potential role of NF-kB and SMAD7 in the cross-talk between NF-kB and TGF-b pathway, and suppression of TGF-b-induced signaling and gene expression. Our findings support a model whereby TGF-b-induced TAK1 enhances NF-kB activation, whereas SMAD7 can attenuate canonical and non-canonical TGF-b signaling, thereby promoting the malignant phenotype of a subset of HNSCC.
RESULTS
Differential expression of TGF-b receptor II and correlation with phosphorylated canonical TGF-b signaling SMAD components in HNSCC tumor tissue and cell lines To examine the prevalence and relationship of TbRII expression to canonical TGF-b-SMAD signaling in HNSCC in situ, we performed immunostaining for TbRII, and phosphorylated (activated) SMAD2 and SMAD3 using a tissue array containing 20 human HNSCC specimens in triplicate, and six normal oral mucosa specimens in duplicate, as summarized in Figure 1a . All normal oral mucosal samples exhibited strong ( þ þ ) TbRII and phosphorylated SMAD2 staining. Strong ( þ þ ) staining for TbRII was observed in 47% (28/ 60) of HNSCC tumor specimens ( Figure 1a , higher magnification, Supplementary Figure 1) , and was significantly correlated with staining for activated p-SMAD2 and p-SMAD3 (P ¼ 0.0001). Conversely, 53% (32/60) of the tumor specimens showed decreased or absent ( ± ) expression of TbRII protein, associated with decreased levels of phosphorylated SMAD2 and SMAD3. Together, these observations indicate that expression of TbRII and phosphorylation of immediate downstream canonical signaling substrates are related, in subsets of HNSCC tumors.
To identify human HNSCC lines that exhibit similar patterns of expression and phosphorylation of TGF-b signaling components, we compared expression and phosphorylation of TbRII and SMADs in primary human oral keratinocytes (HOK) and a panel of nine UM-SCC cell lines (Supplementary Table S1 ) 24 by western blot (Figure 1b ). When compared with HOK, expression of TbRII was similar or greater in 5/9 (56%; UM-SCC1-11B) and attenuated in 4/9 (44%; UM-SCC22A-46) cell lines, as reported previously. 9 Expression of TbRII, SMAD2, p-SMAD2, SMAD3, p-SMAD3 and SMAD7 was detectable in HOK and 8/9 of the UM-SCC lines, providing evidence for functional activation of TGF-b receptor and canonical SMAD signal components. An exception was UM-SCC 46, in which decreased expression of the TGFbR2, p-SMAD3 and SMAD7 protein was found to be due to mutation in TbRII by sequence analysis (J Burnett, unpublished data, not shown).
Canonical TGF-b signaling in HNSCC cell lines is intact but attenuated As previously shown, HNSCC cell lines appear to be refractory to TGF-b-mediated growth arrest, which can be attributed in part to defects or attenuated expression of signaling components. 9, 25 To determine the functional responsiveness of canonical TGF-b-SMAD signaling in HNSCC lines, we compared the effect of TGF-b1 on SMAD phosphorylation in HOK and three UM-SCC lines. In HOK cells, treatment with TGF-b1 for a short interval of 1 h strongly induced phosphorylation of SMAD2 and SMAD3 signal pathway component activation, without significantly modulating total SMAD 2, 3 or 7 proteins (Figure 1b Relationship between TbRII, TAK1 and RELA/p65 in HNSCC tumors and TGF-b1-induced TAK1-NF-kB signaling in HNSCC lines NF-kB subunit RELA (p65) exhibits aberrant nuclear activation in a major subset of oral premalignant lesions and HNSCC in association with poor prognosis, 26 but the signal pathways responsible for NF-kB activation in HNSCC remain to be fully defined. 10 TGF-b and TbRs can also potentially activate and stabilize expression of TAK1 protein and activate NF-kB. 16, [27] [28] [29] [30] Thus, we examined the possible relationship between TbRII, TAK1 Figure 2B ). Functionally, TGF-b1 also induced a significant increase in NF-kB luciferase reporter gene activity in two independent UM-SCC lines by 24 h (Figure 2d ). Taken together, these findings support the hypothesis that TGF-b is able to activate canonical IKK-NF-kB signaling through activation of TAK1. Knockdown of TAK1 by siRNA suppresses NF-kB signal activation, cell proliferation, migration and invasion To further establish whether TAK1 mediates constitutive, TNF-aand TGF-b-induced TAK1-IKK-NF-kB activation, UM-SCC 6 cells were treated with TAK1 siRNA, and cultured for 48 h in serumcontaining medium alone, with added TNF-a for final 8 h, or with TGF-b for final 24 h (Figure 3a) , based upon optimal effects of TGFb on NF-kB-luciferase reporter activity (Figure 2d ). TAK1 siRNA similarly depleted TAK1 expression in UM-SCC 6 cells cultured without or with added TNF-a, and less completely with the longer exposure to TGF-b (Figure 3a) , consistent with TGF-b-induced stabilization of TAK1 protein. 30 In untreated, TNF-a-and TGF-btreated cells, TAK1 depletion inhibited phosphorylation of IKKa/b, IkBa and p65-ser-536 compared with control siRNA. TNF-a and TGF-b markedly induced degradation of total IkB, and increased cytoplasmic to nuclear translocation of NF-kB subunit p65 (Figure 3a ; densitometry, Supplementary Figure 3A) , even though the TGF-b-induced increase in p-p65 observed at earlier time points (Figure 2c; Supplementary Figure 2B) , was attenuated by 24 h exposure. Conversely, TAK1 siRNA partially inhibited IkB degradation and cytoplasmic-nuclear p65 translocation. As only a small increase in resynthesis of IkB was detectable with TAK1 depletion in cells continuously exposed to both factors, we transfected a plasmid expressing an IkB-luciferase fusion protein, which can serve as a quantitative reporter of IKK kinase-induced degradation of IkBa protein. 31 Relative to IkB-luc signal in cells with no treatment, TGF-b and TNF-a treatment induced IkB-luc protein degradation (Figure 3b , left panel). Conversely, knockdown of TAK1 significantly attenuated constitutive, TGF-b-and TNF-a-induced degradation of the IkBa-luc fusion protein (Figure 3b, left panel) . TAK1 siRNA also suppressed constitutive, TNF-a-and TGF-b-induced activation of an NF-kB-specific reporter gene (Figure 3b , right panel), consistent with inhibitory effects of TAK1 siRNA on p65-ser-536 phosphorylation (Figure 3a) , which is required for NF-kB target gene transactivation. 18, 19 Conversely, transient transfection of exogenous TAK1 protein, further enhanced constitutive, TGF-b1-and TNF-a-induced NF-kB reporter gene transactivation (Supplementary Figure 3B) . Knockdown of TAK1 also lowered constitutive, TNF-a-and TGF-b-induced nuclear NF-kB p65 binding activity (Figure 3c, left panel) , and NF-kB-inducible target gene IL-8, as revealed by RT-PCR (Figure 3c, right panel) . Together, the effects of TAK1 depletion on total IkB, nuclear and DNA-bound p65 observed were relatively smaller than effects on IKK-dependent phosphorylation of p65 and NF-kB reporter gene transactivation, consistent with previous findings that modification of nuclear p65 is most critical for its functional activity. 19 Examination of the effects of TAK1 siRNA knockdown on the malignant phenotype of cells demonstrating TGF-b and TAK1 signaling in serum-containing medium (Figures 1b and 2b) revealed that TAK1 promotes cell proliferation (Figure 3d , left panel). However, further supplementation of TGF-b present in serum did not further increase, but slightly inhibited proliferation (Supplementary Figure 3C , upper and lower panels). Thus, we examined whether the canonical SMAD and TAK1 pathways mediate opposing effects on proliferation in 10% serum with or without supplemental TGF-b, by knockdown with TAK1, SMAD2 or both siRNAs. TAK1 siRNA alone inhibited proliferation, whereas SMAD2 siRNA enhanced proliferation, and combination with TAK1 siRNA inhibited this SMAD2 siRNA-related increase in proliferation in serum alone, or with additional TGF-b, consistent with residual Figure 3C) . We confirmed the efficiency of TAK1 and SMAD2 knockdown by qRT-PCR (Supplementary Figure 3D) . Similar partial inhibitory effects were observed with anti-TGF-b antibody attributable to TGF-b in 10% fetal bovine serum, and addition of TGF-b partially overcame the inhibitory effect of anti-TGF-b antibody and increased proliferation, without further increasing proliferation above that attributable to TGF-b in 10% fetal bovine serum (Supplementary Figure 3E) . Together, these observations support a role for TGF-b and TAK1 in promoting proliferation and opposing the inhibitory effects of SMADmediated canonical signaling. TAK1 depletion also partially inhibited matrigel invasion and migration in wound assay ( Figure 3d, right panel; Supplementary Figure 3F) . Thus, these effects of TAK1 depletion are similar to those observed previously with inhibition of NF-kB p65 in HNSCC. 10 Celastrol, a TAK1 inhibitor, inhibits NF-kB signaling and induces apoptosis in HNSCC Celastrol, used as an anti-inflammatory drug in traditional Chinese medicine, 32 has been shown to inhibit TAK1. 23 We examined effects of celastrol treatment on TGF-b-induced phosphorylation of TAK1 and p65 by western blot analyses in UM-SCC 6 deficient for wtTP53, and UM-SCC 22B with mutant TP53 (Figure 4a , densitometry Supplementary Figure 4A) . Treatment with 1.0 or 2.5 mM celastrol for 1 h clearly reduced levels of phosphorylated TAK1 and p65 in both cell lines. Celastrol 2.5 mM could also reduce p-TAK1 and p-p65 over 1-2 h, without reducing total TAK1 (Supplementary Figure 4B) . Furthermore, celastrol treatment reduced constitutive, TGF-b1-and TNF-a-induced NF-kB reporter gene activity (Figure 4b ). Further, celastrol significantly inhibited proliferation of both cell lines in a concentration-dependent manner with EC 50 values ranging from 1.1 to 1.3 mM after 72 h of incubation (Figure 4c ). We next analyzed whether celastrol treatment would affect cell cycle distribution or fragmentation of DNA and Annexin V, which are markers of cell death, by flow cytometry. Celastrol at an inhibitory concentration of 2.5 mM induced accumulation in G2/ M, sub-G0 DNA fragmentation and Annexin V over 12-24 h in UM-SCC 22B, indicative of growth arrest and apoptotic cell death, respectively (Figure 4d, Supplementary Figure 4C ). Similar effects were observed for UM-SCC 6 (data not shown).
NF-kB subunit p65 induces SMAD7 expression and represses TGF-b-SMAD-regulated gene PAI1 in HNSCC SMAD7 is a downstream target of TGF-b signaling, which associates with TGF-bRI and competes with receptor-activated SMADS to inhibit their activation, providing a negative feedback mechanism. 3, 33 Several past studies have reported that SMAD7 may also be induced by or modulate other pathways, including TAK1 and NF-kB. 15, 22, [34] [35] [36] Therefore, we further hypothesized that SMAD7 might be involved in the cross-talk between TGF-b and NF-kB signaling in HNSCC. To examine the potential relation between SMAD7 and NF-kB signaling in HNSCC in situ, we performed immunostaining for SMAD7 and the phosphorylated/ activated NF-kB subunit p65 using a tissue array (Figure 5a , higher magnification, Supplementary Figure 5A) . A total of 73% of the tumor specimens with strong ( þ þ ) p-p65 staining (22/30) also showed strong ( þ þ ) expression of SMAD7 protein. Conversely, only 8% of the tumors with weak (±) p-p65 expression had strong ( þ þ ) staining of SMAD7. This correlation between expression of p-p65 and SMAD7 was highly significant (P ¼ 0.0007), suggesting that NF-kB signaling might contribute to SMAD7 expression.
To examine this hypothesis, we first used TAK1 inhibitor celastrol, which could potentially modulate TAK1-p65-NF-kBdependent SMAD7 expression. Treatment of UM-SCC 6 cells with 2.5 mM of celastrol for 6 h abolished phosphorylation/activation of p65, and inhibited SMAD7 protein levels ( Figure 5b ). As celastrol also inhibited p-SMAD2 (Figure 2b) , and TAK1 has also been implicated in modulating signal SMADs, 37 these findings suggest that phospho-p65 and/or signal SMADs could modulate SMAD7 expression. To further examine the specific role of p65 in SMAD7 expression, UM-SCC 6 cells were transiently transfected with SMAD7 preferentially suppresses TGF-b-induced SMAD and NF-kB activation over constitutive and TNF-a-induced NF-kB activation SMAD7 has been implicated in inhibition of TAK1 activation and canonical TGFb signaling. 15, 22 As we have shown that TGF-b and NF-kB signaling induce SMAD7 expression (Figures 5b and c ; Supplementary Figure 5B) , we explored the effects of SMAD7 modulation on both pathways. UM-SCC 6 cells were transiently transfected with control or SMAD7 vector and treated with 10 ng/ml TGF-b1 for 24 h. Cytoplasmic and nuclear extracts were immunoblotted for TGF-b signaling components (Figure 5d ; separation controls, Supplementary Figure 5C ). Treatment with TGF-b1 induced phosphorylation of SMAD2, especially in the nuclear fraction. Furthermore, overexpression of SMAD7 clearly reduced both cytoplasmic and nuclear phosphorylation of SMAD2 in untreated and TGF-b1-treated cells, indicating an inhibitory effect of SMAD7 on TGF-b signaling. In addition, SMAD7 overexpression markedly diminished TGF-b reporter gene activity by 60% in untreated cells and by 75% in (Figure 5e, upper panel) . Although overexpression of SMAD7 also reduced TGF-b1-induced NF-kB reporter gene activity by 64%, it reduced NF-kB reporter gene activity by only 20% in untreated cells and 24% in TNF-atreated cells (Figure 5e, lower panel) . Together, these results indicate that SMAD7 has an inhibitory effect on both TGF-binduced SMAD and NF-kB signaling, providing a negative feedback mechanism as both pathways induce its expression. However, the inhibitory effect of SMAD7 on TGF-b-induced SMAD or NF-kB signaling is greater than that observed for constitutive or TNF-a-induced NF-kB signaling, providing a basis for preferential activation of NF-kB and inhibition of the downstream canonical SMAD pathways.
DISCUSSION
In the present study, we provide evidence for a novel cross-talk between TGF-b signaling and the NF-kB pathway involving TAK1 and SMAD7 in HNSCC (Figure 6 ). Tissue microarray studies provide evidence linking residual upstream TbRII-SMAD signaling with increased TAK1 expression, and NF-kB activation, in the same subset of HNSCC tumors. We demonstrate that TGF-b1 treatment results in sequential phosphorylation of TAK1 and the canonical NF-kB pathway comprised of IKKa/b, IkB-a and p65 in HNSCC lines. TAK1 depletion blocked activation of NF-kB, cell proliferation, migration and invasion, implicating TAK1 as a key node in aberrant activation of NF-kB and the malignant phenotype of HNSCC. Further studies supported a role for TGFb and TAK1 in countering the inhibitory effects of SMAD2-mediated canonical signaling upon proliferation. Furthermore, we show that NF-kB is linked to SMAD7 expression in the same HNSCC subset, and that both TGF-b and NF-kB induce SMAD7 expression, and that SMAD7 preferentially suppresses constitutive and TGF-b-induced canonical p-SMAD2 signaling and reporter gene activation, relative to effects upon constitutive and TNF-a-inducible NF-kB reporter gene activation.
It is well accepted that loss of growth-inhibitory responses to TGF-b is an important event in early malignant transformation of epithelial cells, 38 including most HNSCC. 25 Subsets of epithelial tumor cells escape from TGF-b-SMAD-dependent effects through defects at different levels of the canonical signal transduction pathway, such as decreased expression of TbRII or SMAD4 in HNSCC. 5, 7, 9, 39 However, only B50% of HNSCC tumors ( Figure 1a ) and cell lines (UM-SCC 22A, 22B, 38 and 46, Figure 1b ) investigated in this study demonstrated relative reduction in TbRII, which may result from repression by mutant TP53 9 or TbRII mutation (J Burnett, unpublished data). TGF-b1 treatment induced detectable phosphorylation of SMAD2, but attenuated TGF-b reporter gene activity (Figures 1c and d) and growth arrest in most of the HNSCC lines examined. 9 Previously, p-SMAD2 was also detected in a majority of HNSCC lines and tumors. 39 Hence, mechanisms other than defects in expression and phosphorylation of upstream canonical TbR-SMAD components must account for the loss of growth inhibitory response, and augmentation of the malignant phenotype by TGF-b in most HNSCC.
Along with attenuation of TGF-b tumor suppressive effects, aberrant nuclear activation of NF-kB subunit RELA (p65) is observed in a major subset of early premalignant lesions and associated with risk of malignant progression and decreased prognosis. 10, 26 Our results provide evidence that endogenous TbRII and TAK1 expression is associated with nuclear NF-kB activation in a subset of HNSCC tumors (Figure 2a) . Further, we provide direct evidence that TGF-b induces NF-kB activation through phosphorylation and activation of TAK1 in HNSCC lines. In addition, we have identified TGF-b-induced TAK1 as an upstream mediator of IKKa/b phosphorylation and activation, leading to phosphorylation and degradation of the NF-kB inhibitor IkBa, and nuclear translocation and transactivation of NF-kB. TAK1 was detected in nucleus as well as cytoplasm (Figure 2a , Supplementary Figure 2A) , consistent with similar distribution in embryonic epithelia 40 and with substrate IKKa/b in HNSCC. 41 Previously, TAK1 has been implicated in NF-kB activation in response to bacterial lipopolysaccharide, TNF-a or IL-1. 13, 14, 42 Here, we show that TAK1 is essential for TGF-b1-as well as TNF-ainduced NF-kB activation, where ectopic expression of TAK1 kinase inactive mutant attenuated TNF-a-and IL-1-induced NF-kB activation. 43 Conversely, we also demonstrate that overexpression of TAK1 augments both TGF-b1-and TNF-a-induced NF-kB activation, highlighting its importance as a key node in regulation of NF-kB in HNSCC.
We further investigated the effect of celastrol, known for its ability to inhibit inflammation and TAK1 activation. 23 Celastrol is a quinone methide triterpene extracted from the root bark of Tripterygium wilfordii Hook F, also known as 'Thunder of God Vine' and has been used in traditional Chinese medicine for decades. 32 Celastrol is reportedly used for its anti-inflammatory activity for the treatment of asthma, rheumatoid arthritis and neurodegenerative disease. [44] [45] [46] Our results indicate that celastrol significantly reduced not only constitutive and TNF-a-induced but also TGF-b1-induced NF-kB activation. This inhibition was mediated through reduced phosphorylation and activation of TAK1 and phosphorylation of NF-kB transactivating subunit p65 (Figure 4) . Celastrol has been shown to suppress TNF-a-induced NF-kB activation by inhibition of TAK1 and IKK activation in human myeloid KBM-5 cells. 23 Furthermore, we showed that celastrol reduced cell density in a dose-dependent manner, which was likely due to growth arrest and induction of cell death, as indicated by G2/M accumulation, sub-GO DNA fragmentation, and increase in Annexin V by fluorescence flow cytometric analysis. Recently, it was shown that celastrol treatment could significantly inhibit tumor growth in a human prostate tumor xenograft model. 47 Although the target effects on NF-kB were not defined as in our study, these results indicate that celastrol may hold potential as a therapeutic agent targeting the pro-oncogenic TGFb-TAK1-NF-kB pathway.
Functional cross-talk between TGF-b and NF-kB signaling in tumor cells has been reported in previous studies. On the one TAK1, NF-kB and SMAD7 in head and neck cancer C Freudlsperger et al hand, TGF-b was reported to suppress NF-kB signaling, through increased activation and expression of IkBa and retention of NFkB in the cytoplasm in B cells, hepatocytes and certain breast cancer cell lines. [48] [49] [50] [51] Conversely, we recently showed that attenuated canonical TGF-b signaling was nonetheless linked with NF-kB activation in another subset of HNSCC.
9 Consistent with our current findings, previous reports have implicated a tumor-promoting effect of TGF-b in the context of prolonged exposure of cells to high levels of TGF-b. 52 In addition, TGF-b2 functions as a potent activator of NF-kB signaling in prostate cancer PC3 cells. 53 TGF-b1 also induced NF-kB; however, levels of TGF-b2 secreted by the prostate cancer PC3 cells were much higher than that of TGF-b1. These findings together with our results showing that TAK1 depletion modulates NF-kB and related proliferative, prosurvival and invasive phenotypes support the hypothesis that TGF-bs may directly contribute to NF-kB activation and related processes implicated in tumorigenesis.
TGF-b signaling may act through the conventional SMADdependent pathway or via alternative pathways independent of SMADs. Generally, SMAD-dependent TGF-b signaling has been implicated in tumor-suppressing effects, 38 whereas SMADindependent pathways have been correlated with tumorpromoting events. 54 Previous studies have revealed that TGF-b can also activate JNK, Erk and p38 MAPK kinase pathways independent from SMADs.
21,34-36 TGF-b1 may activate these pathways by signaling via TAK1, through its function as a mitogen-activated protein kinase kinase kinase. 16 Thus, several alternative SMAD-independent TGF-b pathways besides NF-kB demonstrated herein could also contribute to a switch in signal transduction towards the pro-oncogenic activities of TGF-b signaling observed with cancer progression.
Previous studies have suggested an important role of SMAD7 in the interplay between TGF-b and NF-kB signaling. The NF-kB subunit p65 may suppress TGF-b-SMAD signaling through upregulation of SMAD7. 21 Conversely, SMAD7 can induce IkBa expression, thereby inhibiting NF-kB activation. 55 Our results suggest a more complex role of SMAD7. We found evidence that the inhibitory effect of SMAD7 on canonical TGF-b-SMAD signaling is greater than that upon constitutive and TNF-a-induced TAK1-NF-kB signaling previously defined in HNSCC. 12 This provides a means for preferential inhibition of canonical tumor TGF-b-SMAD signalmediated tumor suppression, relative to effects on constitutive and TNF-a-inducible TAK1-IKK-NF-kB activation, favoring the malignant phenotype. As celastrol inhibits TAK1-mediated NF-kB activation, and promotes apoptosis in HNSCC cells, the alternative TAK1-NF-kB pathway could serve as a potential drug target for developing effective therapies to treat HNSCC.
MATERIALS AND METHODS

Cell lines
The patient characteristics (Supplementary Methods, Supplementary Table S1), molecular and phenotypic characteristics typical of HNSCC tumors and culture conditions have been described for the panel of genotyped University of Michigan squamous cell carcinoma (UM-SCC) lines kindly provided by Dr TE Carey (University of Michigan, Ann Arbor, MI, USA). 24, 56, 57 Primary HOK (ScienCell Research Laboratories, Carlsbad, CA, USA) or Heka used as controls were cultured following the manufacturer's protocol and used within five passages.
Reagents
Recombinant factors and antibodies are described in Supplementary methods.
Immunohistochemistry
Formalin-fixed and paraffin-embedded human HNSCC tissue arrays obtained from Cybrdi were previously described. 58 Detailed immunohistochemistry methods are described in Supplementary Methods.
Western blot analysis
Proteins were separated and immunoblotting were performed using standard methods described in Supplementary methods.
Transfection
Vectors, siRNAs and Methods used are described in Supplementary Methods.
Luciferase reporter assays
Transfection and reporter assays were done as described previously, 38, 59 and in Supplementary Methods. The TGF-b-inducible reporter p3TP-Luc plasmid used, 60 which provides specific readout for TGF-b-mediated signaling 61 was kindly provided by Dr Stuart Yuspa (National Institutes of Health, Bethesda, MD, USA). The IkBa-luciferase fusion protein serves as an indicator of IKK-mediated IkBa degradation and was kindly provided by Dr Louis M Staudt. 31 NF-kB DNA binding assay NF-kB DNA binding activity was assessed using TransAM NF-kB Family Transcription Factor Assay Kit (Active Motif, Carlsbad, CA, USA) following the manufacturer's protocol as described in Supplementary Methods.
Real-time QRT-PCR
RNA isolation and cDNA synthesis and QRT-PCR were performed as previously described 57 and in Supplementary Methods.
Cell proliferation assay
Cell proliferation assay with control or TAK1 siRNA, and with and without Celastrol was performed as detailed in Supplementary methods.
Migration and invasion assays
Scratch migration and matrigel invasion assay with control or TAK1 siRNA were performed as described in Supplementary methods.
Flow cytometry analysis
UM-SCC 6 and 22B cells were plated in 6-well plates and cultured for 24 h. Media was replaced with celastrol at 2.5 mM concentration. At 12 and 24 h, cells were harvested, counted and labeled using the Cycletest Plus DNA Reagent Kit (BD Biosciences, San Jose, CA, USA). Samples were run on a FACS Canto machine within 1 h after labeling, and the data were analyzed using Flow-Jo analysis software (Tree Star, Inc, Ashland, OR, USA).
Statistical analysis
Statistical differences between two groups of data were analyzed using the Student's t-test. The data are presented as mean ± s.d. Immunhistochemistry results were analyzed using Fisher's exact test.
